ValueAct’s Big Year Continues With Third-Quarter Gains

The sometime-activist is on pace to post its best results in six years.

An Olympus Medical Systems LED endoscope. (Tomohiro Ohsumi/Bloomberg)

An Olympus Medical Systems LED endoscope.

(Tomohiro Ohsumi/Bloomberg)

Jeff Ubben’s ValueAct Capital extended its gains in the third quarter in both of its main funds after enjoying a strong first half.

The ValueAct Master Fund rose 1.3 percent in the September period, boosting its gain for the year to 22.2 percent, according to an investor.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related
Sponsored
Sponsored
Sponsored